Fontolizumab (marketed under the trade name HuZAF™) is a humanized monoclonal antibody which is used as an immunosuppressive drug to treat Crohn's disease.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Fontolizumab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Fontolizumab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Fontolizumab. |
| Estrone | Estrone may increase the thrombogenic activities of Fontolizumab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Fontolizumab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Fontolizumab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Fontolizumab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Fontolizumab. |
| Estriol | Estriol may increase the thrombogenic activities of Fontolizumab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Fontolizumab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Fontolizumab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Fontolizumab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Fontolizumab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Fontolizumab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Fontolizumab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Fontolizumab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Fontolizumab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Fontolizumab. |
| Equol | Equol may increase the thrombogenic activities of Fontolizumab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Fontolizumab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Fontolizumab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Fontolizumab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Fontolizumab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Fontolizumab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Fontolizumab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Fontolizumab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Fontolizumab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Fontolizumab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Fontolizumab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Fontolizumab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Fontolizumab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Fontolizumab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Fontolizumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Fontolizumab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Fontolizumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Fontolizumab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Fontolizumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Fontolizumab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Fontolizumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Fontolizumab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Fontolizumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Fontolizumab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Fontolizumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Fontolizumab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Fontolizumab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Fontolizumab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Fontolizumab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Fontolizumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Fontolizumab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Fontolizumab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Fontolizumab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Fontolizumab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Fontolizumab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Fontolizumab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Fontolizumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Fontolizumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Fontolizumab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Fontolizumab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Fontolizumab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Fontolizumab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Fontolizumab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Fontolizumab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Fontolizumab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Fontolizumab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Fontolizumab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Fontolizumab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Fontolizumab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Bavituximab. |
| CR002 | The risk or severity of adverse effects can be increased when Fontolizumab is combined with CR002. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Rozrolimupab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Girentuximab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Obiltoxaximab. |
| XTL-001 | The risk or severity of adverse effects can be increased when Fontolizumab is combined with XTL-001. |
| NAV 1800 | The risk or severity of adverse effects can be increased when Fontolizumab is combined with NAV 1800. |
| Briakinumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Briakinumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Otelixizumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when Fontolizumab is combined with AMG 108. |
| Iratumumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Iratumumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Enokizumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Ramucirumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Farletuzumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Veltuzumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Ustekinumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Trastuzumab emtansine. |
| PRO-542 | The risk or severity of adverse effects can be increased when Fontolizumab is combined with PRO-542. |
| TNX-901 | The risk or severity of adverse effects can be increased when Fontolizumab is combined with TNX-901. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Inotuzumab ozogamicin. |
| RI 624 | The risk or severity of adverse effects can be increased when Fontolizumab is combined with RI 624. |
| Stamulumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with MYO-029. |
| CT-011 | The risk or severity of adverse effects can be increased when Fontolizumab is combined with CT-011. |
| Leronlimab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Leronlimab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Glembatumumab vedotin. |
| Olaratumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Olaratumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when Fontolizumab is combined with IPH 2101. |
| TB-402 | The risk or severity of adverse effects can be increased when Fontolizumab is combined with TB-402. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Caplacizumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when Fontolizumab is combined with IMC-1C11. |
| Eldelumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Eldelumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Lumiliximab. |
| Canakinumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Canakinumab. |